| Names | |
|---|---|
| Preferred IUPAC name | 2-Bromo-2-nitropropane-1,3-diol |
| Other names | 2-Bromo-2-nitropropane-1,3-diol BNPD Bronosol Bromo-nitropropane diol Cereasept Myacide Cis Tos Bronocot |
| Pronunciation | /ˈbrəʊnəpɒl/ |
| Identifiers | |
| CAS Number | 52-51-7 |
| Beilstein Reference | 3580789 |
| ChEBI | CHEBI:31256 |
| ChEMBL | CHEMBL1598 |
| ChemSpider | 6026 |
| DrugBank | DB02438 |
| ECHA InfoCard | 100.024.261 |
| EC Number | EC 200-143-0 |
| Gmelin Reference | 1239284 |
| KEGG | C07287 |
| MeSH | D001980 |
| PubChem CID | 4928 |
| RTECS number | BP5425000 |
| UNII | 3A1VQ33F5O |
| UN number | UN3241 |
| Properties | |
| Chemical formula | C3H6BrNO4 |
| Molar mass | 199.992 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.31 g/cm³ |
| Solubility in water | Miscible |
| log P | 0.18 |
| Vapor pressure | 0.01 Pa (20°C) |
| Acidity (pKa) | 8.61 |
| Basicity (pKb) | 2.72 |
| Magnetic susceptibility (χ) | -74.0e-6 cm³/mol |
| Refractive index (nD) | 1.542 |
| Dipole moment | 2.59 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 190.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -324 kJ·mol⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -2871 kJ/mol |
| Pharmacology | |
| ATC code | D08AJ06 |
| Hazards | |
| Main hazards | Harmful if swallowed or inhaled, causes serious eye irritation, may cause allergic skin reaction, toxic to aquatic life. |
| GHS labelling | GHS02, GHS05, GHS07, GHS09 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H302, H315, H318, H335 |
| Precautionary statements | Precautionary statements: P264, P270, P273, P280, P301+P312, P302+P352, P305+P351+P338, P332+P313, P337+P313, P362+P364 |
| NFPA 704 (fire diamond) | 2-0-2 |
| Flash point | Flash point: 128°C |
| Autoignition temperature | > 250 °C |
| Explosive limits | Non-explosive |
| Lethal dose or concentration | LD50 (oral, rat): 305 mg/kg |
| LD50 (median dose) | LD50 (median dose): Rat oral 180 mg/kg |
| NIOSH | DL8225000 |
| REL (Recommended) | 0.1 |
| Related compounds | |
| Related compounds | Bromochloroacetate Bronidox Bromopropylate |
| Parameter | Details |
|---|---|
| Product Name | Bronopol |
| IUPAC Name | 2-Bromo-2-nitropropane-1,3-diol |
| Chemical Formula | C3H6BrNO4 |
| Synonyms & Trade Names | BNPD, Bronosol, Myacide, Onyxide 222, 2-Bromo-2-nitro-1,3-propanediol |
| HS Code & Customs Classification | 29049090 (exacts may be region-specific and should align with product type and regulatory position) |
Bronopol, produced in several grades, relies on selection of key raw material inputs such as nitromethane and bromine. For industrial-scale batches, initial quality of nitromethane influences the profile of organic byproducts. Bromine purity has a critical impact on downstream color and trace residuals, which presents an ongoing quality control checkpoint during charge preparation and reaction phase.
The synthesis route typically follows controlled bromination and nitration in steps targeting minimized formation of over-brominated or mixed nitroalcohol byproducts. Parameters such as reaction temperature and pH are closely managed, as exothermic response and side reactant control dictate final yield and isolable product grade. Water content in intermediates must be monitored since Bronopol remains hygroscopic and excess moisture in the process can affect stability during drying and packing.
Purification strategies are determined by customer’s end-use sensitivity and regulatory requirements, including cosmetic, oilfield, and industrial water treatment applications. Demands on trace organics, color grade, residual volatility, and particle size drive both filtering and crystallization controls. Bronopol’s grade-specific impurity levels are tied directly to the purification steps employed, varying with the targeted application—pharmaceuticals require more stringent fractions compared to technical types.
Release testing relies on chromatographic purity, defined against a reference compound, and physical specifications such as melting point range and bulk density, with values defined internally or by customer agreement. In-process batch consistency is reviewed through sequential sample analysis, with recurring calibration against control standards to ensure downstream formulation performance, particularly for biocidal effectiveness and formulation shelf-life stability.
HS code assignment is principally based on the chemical structural class. Specific sub-codes may be used if the Bronopol is prepared for use as a formulated biocide or if surface treatment applications necessitate specific documentation. Customs and export classifications are routinely checked to reflect both the chemical and the intended sale region, as ongoing revisions in import regimes affect documentation and shipment clearance procedures.
Handling and downstream storage requirements for Bronopol depend on grade water content and stabilization additives. For instance, packaging for long-haul shipments may involve moisture-resistant liners or inert-gas blanketing, particularly where hydrolysis or caking could impact product flow and downstream dosage uniformity in end-use solutions. Bronopol with low-particle or dusting propensity requires containment, and batch segregation in storage addresses cross-contamination risk if multiple production grades are processed at one site.
Quality and application-specific requirements define the manufacturer’s approach regarding every process segment—raw material traceability, intermediate stability, final purification, and release are each triggered by both customer and regulatory demands, not generic commodity standards.
In industrial settings, Bronopol is commonly isolated as a crystalline solid. The form, color, and apparent purity of the material directly reflect both feedstock quality and crystallization control throughout the batch. Slight color variations can indicate trace-level oxidation or residual synthesis by-products. Distinct odor serves as an early indicator of potential contamination or incomplete purification, typically more noticeable in off-grade or technical grades.
Standard melting and boiling points are consistent for high-purity batches, but manufacturing process variations, especially water content and residual solvent from crystallization, can shift observed values. Density measurement supports verification of batch consistency, with tighter tolerances enforced for pharmaceutical or biocidal grades.
Long-term stability depends on environment. Bronopol demonstrates reasonable stability under dry, sealed storage, but traces of moisture or transition metals in process equipment may accelerate decomposition. Continuous monitoring of batch storage conditions, including humidity and potential for acid/base contamination, becomes essential to maintain integrity during bulk handling. In our facilities, product intended for biocidal applications undergoes additional post-synthesis stabilization.
Solubilization follows typical temperature dependence, but actual dissolution rates strongly depend on particle size and presence of process residues. Application requirements determine physical form granularity and particle control. Process water quality, pH, and the material of mixing vessels can introduce trace metals, which must be controlled, especially for high-purity or injection-grade requirements, due to sensitivity to iron and copper-catalyzed degradation reactions. Industrial-scale solution preparation lines employ deionized water circuits, and periodic solvent switching is scheduled for equipment maintenance to avoid buildup of insoluble residues.
Physical, analytical, and impurity profiles are grade-specific. Regulatory-driven supply (e.g., pharmaceutical, cosmetic, biocidal) defines standard limits, whereas industry-use technical grade accepts broader ranges with supplier-to-customer negotiated criteria. Specification tables remain internal documents, tailored to regulatory filings and customer technical agreements.
Every batch undergoes impurity profiling, primarily targeting nitrosamine precursors, brominated by-products, and residual solvent content. The process route, raw material purity, and crystallization steps drive these impurity signatures. For sensitive uses, in-process sampling tracks trace-level chlorinated or oxidized microcontaminants, especially those arising from upstream raw bromine, formaldehyde, or nitromethane sources.
Release testing is aligned with application end-use. Industry consensus standards reference validated analytical procedures (e.g., HPLC, GC-MS for organic contaminants, toluene extraction for water-insoluble residues). Batch release protocols incorporate customer-supplied or regional methods where market access hinges on compliance with local reporting requirements. Out-of-specification management uses a combination of targeted reprocessing or blending, based on the exact impurity fingerprint.
Purchased raw materials—typically bromine, formaldehyde, and a suitable nitrogen source—undergo incoming QC paneling for purity, water content, and trace metal analysis. The procurement team prioritizes stable supply partners with verifiable origin-traceability and prior audit history. Regional logistics variations, especially for bromine, can drive temporary route adaptations or toll-manufacturing outside standard sites if global shortages occur.
Most production adopts a controlled aqueous-phase route, which balances process scalability and effluent management. Reaction control mechanisms focus on temperature profile, stoichiometric charge, and acid scavenger addition, aiming to minimize secondary brominated or polymeric by-products. Process choice reflects both regulatory registration and downstream use requirements; for critical applications, additional post-synthesis purification is scheduled.
Automated PLC systems drive real-time monitoring of reaction pH, temperature, and endpoint titration. Critical process control points include in-line sampling at defined intermediate formation stages, anti-foaming agent dosing, and filtration regime switching. Purification strategies rely on multi-stage crystallization and solvent stripping. Recycle streams and waste minimization protocols are constantly refined, particularly as global regulatory pressure on brominated effluents intensifies.
Quality control combines classical wet-chemistry assays and instrument-driven spectroscopic confirmation. Each batch release hinges on defined acceptance criteria for key properties: assay, residual water, impurity fingerprint, and solution clarity. Reject rates connect directly to upstream feedstock fluctuations and equipment cleaning intervals. Release standards remain dynamic, always subject to customer-specific requirements and batch history.
Bronopol acts as an electrophilic brominating agent and serves in nucleophilic substitution pathways in water-based systems. It demonstrates reactivity under both acidic and alkaline conditions, with selectivity highly grade-sensitive. Residual metal content and pH drift create variable rates for hydrolysis or reductive de-bromination during storage and blending, which need monitoring in process flows.
Catalyst-free operation dominates standard routes, but alternative protocols can introduce weak acid or amine catalysts for yield optimization. Temperature management is crucial to minimize side product formation, especially in high-throughput environments. Solvent choice—primarily water, but also select alcohols or glycols for specialty processing—depends on customer-specified downstream solubility and formulation compatibility requirements. These factors drive periodic process optimization reviews.
Bronopol feeds into various derivative chemistries, notably biocidal formulation blends, specialty intermediates, and certain pharmaceutical excipients. Modification paths, such as conversion to higher brominated intermediates or tailored molecular scaffolds, depend on raw material grade and application-driven impurity profiles. Feedback from downstream formulation customers drives continuous improvement of impurity control in our process.
Temperature and humidity represent prime risk factors in bulk storage. Premises are fitted with climate controls, and desiccant systems are maintained for high-value grades. Bromopol remains light-sensitive; storage away from direct sunlight and strong UV sources prevents unwanted degradation. Nitrogen-inerting or vacuum packaging becomes standard for sensitive lots, expected to remain in storage beyond scheduled turnover.
Corrosion-resistant and non-reactive containers (HDPE, glass-lined steel) protect both product and handling personnel, especially in regions with high ambient humidity or temperature fluctuations. Periodic compatibility audits check for evidence of leaching and cross-contamination. Bulk transit may employ customized liners to safeguard purity for regulated customers.
Shelf life varies with storage environment, packaging integrity, and product grade. Most grades show stable assay values over planned distribution windows, though elevated temperatures or exposure to metal ions accelerate visible degradation—color darkening, odor change, caking. Warehousing teams are trained to monitor such signs at every re-inspection checkpoint. Batch age and storage log traceability form part of the batch release documentation for all pharmaceutical and biocidal customers.
Bronopol carries hazard designations as per national chemical safety standards, including adverse effects on skin, eyes, and aquatic environments. Classification depends on impurity profile and application context; GHS labels in manufacturing facilities highlight key risk categories based on actual batch analytical results, not theoretical maximums.
Operator training includes handling protocols for all hazard-coded Bronopol grades. Material Safety Data deployment relies on process-integrated signage, spill response programs, and pre-labeled packaging tailored for each storage zone. Exposure minimization at all transfer points focuses on engineering controls, not just PPE reliance.
Toxicity reflects acute and chronic exposure, both by inhalation and skin contact. Risk mitigation depends on enclosed systems, automatic transfer, and incident monitoring. Production workers consult safety panels for up-to-date toxicological alerts, as new findings or regulatory shifts can redefine acceptable exposure limits. Customer technical consultations address safe-use integration in downstream mixing, especially for non-industrial end-users.
Annual production volumes for Bronopol fluctuate based on plant utilization rates, raw material sourcing stability, and scheduled maintenance activities. Output for high-purity and pharmaceutical grades remains lower by necessity due to extended purification and batch segregation procedures. For general industrial applications, larger batch campaigns are typical, but upscaling depends on stable access to key intermediates such as 2-bromo-2-nitro-1,3-propanediol and the nitric acid derivatives utilized in core synthesis. Capacity bottlenecks usually trace back to upstream raw material interruptions or constraints in plant-side energy allocation.
Standard lead times for consistent specification requirements align with material flow planning—ranging from two to six weeks under normal load. Custom grades, extended analytical documentation, or regional certification demands can extend response times, as validation and alternate sample retention require extra quality reviews. MOQ typically reflects downstream storage and logistical considerations; for bulk packaging, this commonly equates to multiple pallet loads, while smaller lots serve specialty and regulatory-critical orders.
Industrial production supports several packaging formats: high-density polyethylene drums and composite fiber containers dominate for bulk logistics, minimizing moisture ingress and mechanical degradation risks during transit. Pharmaceutical and specialty cosmetic grades rely on tamper-evident, multilayer polymer or aluminum-laminated packaging, with inner liners for enhanced product isolation where end-use mandates sterility or trace contaminant minimization.
Shipping is primarily FOB main port or CFR destination for consolidated full-container loads. For hazardous cargo requiring UN-compliant transit, carriers and third-party handlers are selected based on their chemical-specific documentation and incident history. Payment terms often settle around LC at sight or TT pre-shipment for new supply contracts, with negotiated post-shipment terms available for repeat clients with established risk mitigation and insurance arrangements.
Bronopol’s cost structure derives from direct inputs such as bromine compounds, nitroalkanes, and primary alcohols. The upstream bromine supply chain is sensitive to global elemental bromine market swings and output rates from major brine extraction and refining hubs. Fluctuations arise during regulatory tightening (for example, local production quotas or environmental crackdowns affecting brine extraction), while nitromethane and related reagents experience spot volatility from downstream solvent and fuel additive market shifts. Souring or price spikes in these feedstocks translate almost directly to adjusted contract or spot offers.
Pharmaceutical and regulated biocidal grades show marked price separation compared to technical or legacy industrial grades, reflecting analytical control, batch certification, and expanded impurity management. End-use application, such as water treatment, requires less stringent certification, allowing economies of scale. Downstream customers seeking REACH compliance or tailored regulatory documentation incur higher per-kilogram pricing due to extended QC records and tailored packaging. Product purity and residual contaminant thresholds set the baseline for price bands; sub-lot and off-grade material typically carries a variable discount, subject to risk acceptance in the target process.
Patterned demand emerges from biocidal, preservative, and pharmaceutical intermediate markets, with notable consumption by water treatment and personal care applications in the EU, US, and parts of Asia. Southeast Asia and India constitute growing demand centers as end-use sectors in personal care, textile treatment, and process water conditioning expand. Production overhang or inventory buildup on the manufacturing side quickly depresses prices within these regions, though high-certification demand (EU, US) cushions some volatility through fixed-term supply contracts.
US buyers emphasize verified cGMP production, full FDA/US EPA registration, and US DOT-compliant shipping, favoring local or treaty-aligned suppliers where possible. The EU market raises the bar on REACH documentation and dual-use contaminant declarations, promoting price premiums for EU-based or closely allied manufacturers. Japanese customers demand robust traceability, consistent batch performance, and detailed heavy metal trace results. Indian and Chinese end-users dominate the expanded industrial grade volume, with fluctuating regulatory interventions leading to intermittent supply-side squeezes and arbitrage opportunities. Domestic policy swings (such as new Chinese environmental regulations or Indian anti-dumping reviews) create periodic export surges or bottlenecks.
Current forward-looking models, referencing public procurement data and input commodity trend lines, suggest gradual cost pressures upward through 2026, with episodic volatility from upstream bromine pricing, especially if further regulatory restrictions or resource consolidation manifest in China or the Middle East. Surplus inventory in Southeast Asia mitigates sharp price surges, although persistent regulatory alignment costs in North America and the EU continue to fragment the pricing landscape by grade and documentation requirements. Eco-label and green chemistry mandates set to roll out could also raise manufacturing overhead for compliant batches.
Market analysis refines consensus from published customs data, trade association bulletins, and raw material futures, triangulated with quarterly disclosures from major chemical manufacturers and audited capacity assurance reports. Internal tracking augments this structure with direct input cost indices and batch release deviation log summaries to map pricing pressure points.
Notable disruptions in bromine extraction regions have pressed feedstock availability through the previous year, with manufacturers reporting temporary slowdowns or substitution efforts for certain grades. Some pipeline manufacturers are investing in backward integration along the bromine derivatives value chain to buffer against supply risk.
EU authorities updated technical dossier requirements for biocidal registrations, with more demanding trace impurity and toxicology verification. US and EU regulators have sharpened focus on nitrosamine contaminants, prompting specification tightening for pharmaceutical and personal care suppliers. Indian regulators initiated spot audits on imported intermediate stocks to counter non-compliant labeling, affecting supplier lead time calculations.
Process engineers have shifted to secondary bromine sources and have expanded local purification for critical grades, lengthening production cycles but stabilizing output. Batch record review frequency has risen in response to evolving customer documentation demands and to head off the risk of cross-contamination. Internal risk mitigation centers on increased raw material pre-purchase and alternate supply route mapping, especially in anticipation of further regulatory escalation or logistics bottlenecks.
From the factory floor, Bronopol serves as a trusted biocidal active in several key sectors. In industrial water treatment, operators rely on its proven action against microbial contamination in process water, cooling towers, and paper mill systems. Formulators in personal care and cosmetics use Bronopol within permitted limits, targeting preservation against bacteria in creams, lotions, and wet wipes. Oilfield operations draw on its capacity to manage biofouling in both upstream and downstream applications. Manufacturers of adhesives, paints, and coatings integrate Bronopol to extend product shelf stability and combat in-can microbial growth. Each sector introduces its own operational constraints, regulatory frameworks, and compatibility needs, shaping which grade of Bronopol comes into play.
| Application Sector | Common Bronopol Grades Used | Common Impurity & Quality Focus | Key Application Factors |
|---|---|---|---|
| Industrial Water Treatment | General Industrial Grade | Formaldehyde & Dioxane levels, Particle contamination | Dispersion in aqueous systems, compatibility with water chemistry |
| Personal Care & Cosmetics | Pharma/Cosmetic Grade | Low heavy metals, controlled trace organics, low residual solvents | Ingredient purity, low allergen profile |
| Paper & Pulp Processing | General Industrial Grade | Particle-free, low ash, managed volatile residue | Pulp process compatibility, dosing control |
| Oilfield Biocides | Technical/Industrial Grade | Chloride content, stability under field conditions | Temperature resistance, solubility in hydrocarbons |
| Paints, Adhesives, Coatings | Industrial Grade, Sometimes High-Purity Grade | Color stability, impurity impact on final product properties | Formulation impact, visible residue after drying |
In manufacturing, the primary parameters to track for Bronopol include crystalline purity, free water content, residual formaldehyde, and the level of organic and inorganic contaminants. For water treatment and paper production, bulk process grade targets focus on low insoluble residues and trusted microbiological performance over time. Cosmetic and pharma applications demand a distinct manufacturing line, minimizing process-borne contaminants and targeting stricter analytical release standards. Each downstream processor checks for compatibility between Bronopol and system additives, as traces of process impurities like chlorides or amines occasionally impact emulsion stability or odor profile in finished products.
Clarity about the end-use helps the production department set the correct process conditions. For a formulator producing a rinse-off cosmetic, the approach requires stricter microbiological and purity constraints. For an oilfield operator dosing a water injection system, chemical robustness and cost efficiency usually take priority.
Regulatory status drives both raw material selection and batchwise QC release. European and US cosmetic regulations, for example, stipulate impurity limits and require non-animal tested sources for personal care. In biocidal product registration, only specified technical grades receive approval. The regulatory manager works closely with operations to confirm these alignments before confirming a supply batch.
Certain sectors tolerate minor process impurities, such as trace formaldehyde, while others—like facial care or injectable products—reject materials with detectable by-products. Production routes get adjusted accordingly. Consistent process monitoring, in-line filtration, and targeted post-reaction purification filter out metallic, mineral, or organic traces as mandated. Quality control sets the release gate based on the customer spec and prevailing regulations.
High-volume industrial applications lean towards larger-lot technical grades, balancing quality with cost management. Low-volume, boutique personal care or specialty analytical uses typically require smaller, more tightly screened lots—often resulting in higher per-unit raw material outlay. Manufacturing balances batch planning and process scheduling to prevent cross-contamination and secure product homogeneity.
Operational reliability relies on customer-side validation. The technical support team provides representative samples matched to the customer’s proposed downstream processes, triggering a site-specific evaluation. Feedback on dispersion, odor, compatibility, and stability directs further grade tweaking—allowing for development of tailored solutions if standard grades don’t fit operational or product performance criteria.
Bronopol manufacturing runs under verified quality management systems. Our production site operates under ISO 9001 certification, verified by accredited auditing bodies. Certification scope covers product development, raw material intake, in-process controls, and batch release. The certification status supports regular internal audits and ongoing compliance assessments. Auditors review nonconformities and corrective actions on a documented schedule, covering both finished product performance and supporting procedures. Regular training ensures every production team member understands deviations, traceability, and documentation requirements.
Requirement profiles for Bronopol differ by destination and intended use. Regulatory dossiers and registrations—such as REACH registration for the EU market and other regionally mandated product authorizations—define minimum purity, maximum allowable impurities, and required analytical controls. These registrations draw boundaries for trace composition and dictate in-plant segregation, pre-release sampling, and documentation structure. For certain pharmaceutical or personal care applications, further documentation may be required: audit reports, substance flowcharts, and GMP compliance declarations, if the end-use demands it. Customers with custom requirements receive tailored certification packages reflecting batch-specific quality results and traceability chains back to raw materials.
Every Bronopol batch leaves the plant with its own set of release documents. Certificate of Analysis (COA) templates reflect product grade, major purity indicators, and application-specific residual impurity requirements. Factual deviations from previous batch results are flagged and investigated in quality reports. Requestable documentation includes full analytical result sets, deviation reports, and raw material certificates, depending on client request and contractual agreement. Long-term supply relationships often involve deep-dive quality reports and audit trails, addressing both batch-to-batch consistency data and incident resolution files. Document archiving follows regulatory and customer requested retention timelines.
Steady Bronopol availability depends on the integrity of our core production asset base and forward planning of critical raw materials. Manufacturing runs according to an annual forecast schedule, with capacity adjustment options triggered by contracted volume commitments, historical demand, and market signals. Peak demand orders or customer expansion conversations are handled with dedicated technical and production planners on-site. Flexibility stems from direct manufacturer-to-end-user discussions, not a cookie-cutter policy. Business cooperation models—spot deals, scheduled deliveries, and blanket order arrangements—are set based on downstream storage, shipment lead time, and market volatility.
Bronopol output hinges on upstream intermediate quality and process stream management. Each production block features dedicated reaction, separation, and drying systems for Bronopol. Maintenance windows, batch traceability, and redundancy strategies are tuned to mitigate unplanned downtime, directly influencing batch consistency. Batch sizes and lot organization reflect both domestic and export logistics constraints as well as truck or container compatibility. Technical sales staff and plant schedulers meet regularly to coordinate order book priorities, inventory levels, and finished goods allocation. Long-term customers benefit from reserve capacity options and emergency production slots, subject to predefined supply agreements.
Sample requests for Bronopol reference current production, not legacy batches. Requests require technical application information—such as intended industry, formulation specifics, and downstream regulatory requirements—to determine suitable grade and specification. Every sample dispatch is paired with a minimum set of quality documents. Fulfillment is tracked and documented in both laboratory and logistics records, ensuring trace batch alignment with later commercial shipments. Follow-up technical support and feedback loops interface directly between customer formulator and our technical team, supporting new product development or process scale-up feedback.
Flexible cooperation models rely on full visibility of both supply-side constraints and demand-side requirements. Short-notice production runs and customized packaging options are available for specialized downstream applications. Contracts may define rolling delivery schedules, buffer inventory holdings at our regional warehouses, or just-in-time delivery sets for high-turnover users. Both fixed price and index-linked models can be arranged, depending on the length of commitment and predictability of feedstock prices. All customers, regardless of contract type, are supported by direct access to our technical, quality, and logistics teams, ensuring rapid issue resolution and technical alignment throughout the collaboration lifecycle.
Research activities for Bronopol focus on impurity management, stability optimization, and compatibility with diverse formulation systems. In our plant, controlling trace aldehydes and nitrosamine precursors during synthesis ranks as one of the principal technical tasks, since different applications such as personal care, adhesives, and industrial water treatment require tailored impurity profiles. Recent projects target the minimization of residual organic solvents and by-products, driven by both regulatory tightening and end-user performance feedback.
Bronopol finds new relevance in preservation regimes for high-water-content formulations, including cutting fluids and household cleaning products. Trends show rising demand for blends with other biocides designed to combat resistant microbial strains, and for use in multiphase systems where separation and activity loss can arise. Some regions now investigate Bronopol for low-dose spot treatments in specialty coatings where legacy preservatives face regulatory restrictions.
Consistent particle size control, especially in powder grades, remains a recurring production challenge, as variability can impact dissolution rate and distribution in aqueous systems. Breakthroughs align most with improved crystallization control and innovative purification steps to reduce residuals from both upstream and downstream processing stages. Our team dedicates ongoing effort to both in-process analytical development and batch reproducibility, as variation affects both product safety and downstream process yields for customers.
Demand projections indicate steady to moderate growth across water treatment, coatings, and specialty formulation sectors. Some adjustment in volumes may occur as regulatory bodies tighten exposure limits and as customers adopt multi-preservative blends for broader spectrum coverage. Novel technical applications such as microencapsulated Bronopol or slow-release matrix systems are under early investigation but not yet commercialized at scale.
Process evolution continues toward closed-loop solvent recovery, in situ monitoring of critical impurities, and reduced energy consumption per batch. Local and international regulations push for transition away from legacy process aids and minor raw components now flagged for safety or environmental review. Where possible, we refine stepwise feeding, automated temperature ramping, and slurry handling to cut both batch cycle times and waste volumes.
Adoption of greener synthesis routes, such as swap-in of renewable or lower-impact feedstocks, advances as market and regulatory pressures mount. Solvent recycling systems and by-product valorization lead internal improvement cycles. Where customers request, we supply Bronopol free of specific solvents or with full impurity mapping to support green labeling. Full transition to green chemistry for all grades depends on both raw material supply security and downstream user adoption of potentially altered product profiles.
Our technical service group routinely advises on Bronopol solubility characteristics, reactivity with potential co-formulants, temperature stability during freight, and impact of storage conditions on shelf stability. Recommendations differ for customers working with oil systems versus waterborne systems, as interaction profiles and dosing logistics vary. Users receive access to grade-specific technical sheets developed with real-time batch data and regular updates reflecting new process analytics.
Support staff collaborate on site and remotely to address challenges like phase compatibility, precipitation during storage, or unexpected color drift. Adjustments in dosage and grade selection are recommended based on actual trial feedback, and in some cases, we conduct parallel lab validation to reproduce user-observed issues. Product grades undergo formulation screening tests to assist in selecting the most reliable type for each application field, with attention to downstream process impacts such as reactor fouling or filterability.
Follow-up service includes re-testing of retained samples, rapid deployment of technical teams for troubleshooting, and provision of process optimization insights for both routine and custom-order lots. All after-sales support respects the confidentiality of both customer formulations and process data. Nonconformance claims are processed based on full batch traceability and transparent review of analytical and production histories. Internal release criteria reflect agreed customer specifications and in-house continuous performance assessment.
We operate the entire production process of Bronopol, from raw material selection to finished product packing. Process control programs at each synthesis stage limit byproducts and allow for batch consistency that commercial customers expect. Bronopol leaves our plant only after it meets specifications demanded by technicians who understand the chemical’s roles in multiple industries.
Factories and process operators depend on Bronopol as a fast-dissolving, high-activity biocide and preservative. Our output supports water treatment facilities, metalworking fluid blenders, oilfield service teams, and paper production plants worldwide. Technical specialists rely on this molecule to manage bacteria, safeguard recirculating water loops, inhibit slime in papermaking machines, and extend fluid shelf life. Customers in these fields turn to source manufacturing for uninterrupted availability and predictable composition.
Bronopol output meets industry-relevant technical standards, as tracked by our in-house labs. Analytical chemists test every lot against measurable targets for purity, active ingredient, moisture content, and trace residuals. Batch data is captured in digital control records. Our site’s vertically integrated supply structure allows us to react quickly if new specifications arise or special process requests appear. Whether the shipment fits a drum or bulk-tanker, document-backed product traceability comes as part of our offering.
We fill and seal Bronopol in standard and custom-sized packaging at our facility, covering small drums to lined, industrial-scale bulk containers. Each packaging type supports safe storage and transport. On-site warehousing and continuous output allow us to maintain fill rates and manage scheduled dispatch for industrial users and repeated purchasing teams. End buyers that plan month-by-month drawdown or require just-in-time delivery gain direct control of their upstream inventory pipelines.
Technical support goes beyond order fulfillment. Our plant’s technical staff works with industrial buyers to recommend dosing protocols, address compatibility with other additives, and solve process integration challenges. Field application feedback is discussed with production engineers, leading to stepwise upgrades in quality and packaging approaches based on what customers report from their own operations.
Direct engagement with our manufacturing plant gives commercial buyers a reliable channel for material planning, compliance, and supply chain transparency. In-house production knowledge supports procurement professionals during project scoping, cost model adjustments, and supply risk assessments. By eliminating unnecessary intermediaries, decision-makers get confidence in traceability, production schedules, and documentation. No gaps in delivery. No surprises in composition.
| Sector | Main Use of Bronopol |
|---|---|
| Water Treatment | Control of microbial growth in cooling and process water |
| Oil & Gas | Bacterial management in injection and recovery processes |
| Metalworking | Preservation of metalworking fluids |
| Pulp & Paper | Microbial protection in production and finished stock |
For manufacturers, distributors, and procurement teams, a direct relationship with source production anchors supply continuity and supports compliance. Every metric ton shipped from our facility reflects operational control, chemical knowledge, and an understanding of how Bronopol drives efficiency in downstream industry.
Bronopol, known in-house as 2-bromo-2-nitropropane-1,3-diol, remains one of the mainstay biocides in our production line for industrial water treatment applications. Since we began synthesizing this molecule decades ago, we have worked continuously to refine its purity and stability based on direct experience in feedback from on-site technical teams at end-use plants. Our team focuses on maintaining strict lot-to-lot consistency in appearance, solubility, and activity, ensuring the downstream reliability our customers expect.
In our reactors, Bronopol presents as a white-to-off-white crystalline solid. Our finished lots leave the plant with active ingredient content typically between 99% and 100% by weight, as confirmed by in-house HPLC analysis. This high assay content minimizes bulk usage and supports predictable dosing in the field.
Bronopol is prized for its water solubility, at about 25 g per 100 mL at 25°C. This helps plant engineers prepare stock solutions quickly and avoid clogging or sedimentation in chemical dosing equipment. In over two decades of regular production runs, our technical staff has observed excellent cold-water solubility and minimal precipitation under typical dosing concentrations, a significant benefit in colder climates or closed-loop systems with variable temperature conditions.
On a molecular level, Bronopol acts as an oxidizing agent, disrupting the enzymes essential for microbial metabolism in recirculating water systems. In controlled pilot studies and in-field feedback, we’ve seen reliable performance in controlling bacteria and fungi at usage levels often ranging from 10 to 50 mg/L, though optimal dosage depends on system load and degree of contamination. Our technical support team works closely with operators to recommend safe and compliant concentrations that align with local discharge limits.
Compatibility with standard industrial materials is critical: Bronopol typically shows low reactivity with metals commonly found in system piping, including carbon steel and nonferrous alloys, when dosed and monitored correctly. Our R&D lab tests every batch on metal coupons for corrosion inhibition to avoid downtime or maintenance costs downstream. It’s worth noting that Bronopol may react with strong reducing agents and some amines. Overdosing or improper blending can lead to the release of trace formaldehyde, so adherence to our technical bulletins and engineering consultation is essential for safe, long-term operation.
As a manufacturer, our finished Bronopol leaves the plant packed in high-density polyethylene containers, with drum sizes ranging from 25kg to 500kg for bulk users. Tight control of moisture and oxygen exposure during warehousing preserves stability, typically up to 24 months from date of manufacture, based on our internal shelf-life studies. Our shipping documents always include a technical certificate with solubility, active content, and moisture content data confirmed from the final lot analysis.
Many water utilities and industrial clients ask about regulatory status and safety. Our Bronopol complies with widely accepted thresholds for discharge and workplace exposure, in line with established industry guidelines. We have invested in modern environmental monitoring for our processes to minimize effluent and control raw material sourcing. Our technical specialists will address system-specific requirements and can assist with documentation when customers require traceability or third-party audits.
We maintain a continuous improvement cycle in every batch, backed by analytical testing, on-site customer visits, and ongoing investment in process control equipment. For end-users seeking detailed specification sheets or hands-on support, our in-house laboratory and engineering staff offer practical guidance—reflecting the realities of industrial-scale usage, not just theoretical performance. In industrial water treatment, making the right choices in biocide chemistry keeps systems running efficiently and safely, and long-term partnerships matter as much as the chemistry itself.
Over years of producing Bronopol at scale, we see buyers often ask about minimum order quantity and lead time—that’s no surprise in today’s procurement climate. Large buyers in water treatment, personal care, and industrial preservation want certainty and transparency well before purchase. For a chemical like Bronopol, firming up these basics reduces downstream risk and shapes production schedules both for us and for our clients.
Our minimum order quantity for Bronopol sits at 500 kilograms per batch. This floor fits with our production line efficiency, packaging equipment, and raw material sourcing. At this volume, buyers leverage pricing stability, and we maintain high process control with every batch. Smaller quantities tend not to justify the setup effort and quality assurance testing required for regulatory compliance. By setting a practical MOQ, we guarantee both cost effectiveness and batch-to-batch consistency that meets what end users expect.
For larger scale projects—single orders exceeding several metric tons—we offer tanker truck shipping or custom container solutions. Our operations infrastructure supports this scale without affecting specification or documentation. Direct engagement with our logistics team enables buyers to time receipt of Bronopol based on true project needs, supporting just-in-time inventory systems for plant downstreaming or contract manufacturing scenarios.
Average lead time for Bronopol bulk orders runs two to three weeks from confirmed purchase order. All manufacturing steps—from raw material vetting and reactor charging to filtration, drying, milling, and packaging—take place inside our own facilities. This gives us visibility into each stage. For ongoing contracts or annual delivery schedules, we offer slot reservation in our production calendar. This helps procurement teams plan months in advance and avoids spot market volatility, especially during peak demand periods.
Packaging choice also affects lead time. Standard packaging includes fiber drums with poly liners or jumbo bags, based on required tonnage and handling constraints. For orders that specify non-standard packaging or additional batch documentation, there may be a few extra days for validation. Our in-house QA/QC laboratory runs full parameter checks per batch, and we keep retention samples for traceability should any regulatory bodies audit downstream.
Direct engagement between our production planners and client procurement teams strengthens agility. Early sharing of usage forecasts lets us source raw materials proactively, securing pricing and eliminating order delays. Bronopol depends on feedstocks that can fluctuate in global supply. Knowing aggregated demand in advance—especially for clients aligned with regulatory changeovers or product launches—boosts on-time performance and keeps working capital locked in where it’s needed.
For urgent projects or expedited shipments, our team consults with the buyer to review option pathways. We have periodically run split-shipments to cover gaps if end users need a partial delivery ahead of the full lot. This flexibility grows out of long-term partnership, trust, and our commitment to supporting customers’ production continuity.
Manufacturing Bronopol at scale means balancing operational discipline with market responsiveness. MOQ and lead time represent entry points to a wider partnership, grounded in reliability, technical support, and a transparent supply chain. By keeping these aspects clear and predictable, we deliver confidence that underpins every ton we produce.
Bronopol’s chemical stability and purity rely on how it is stored from the moment we finish the batch to the point it reaches your facility. We manufacture to order, so every shipment leaves our plant with a certificate of analysis, handled by staff trained in hazardous chemical protocols. Our dry storage warehouse maintains temperatures below 25°C and avoids direct sunlight and moisture exposure—two common triggers for product degradation. Bronopol absorbs water from air rapidly and breaks down when exposed to heat or light. Sealed, high-density polyethylene drums or fiber drums with liners form our standard packaging, keeping the material dry during transit and storage. Our containers carry tamper-evident closures and clear hazard labelling according to international transport rules.
Exporting Bronopol draws regulatory scrutiny from many agencies given its biocidal function and classification as a hazardous substance. Our logistics and compliance departments stay updated on REACH (Europe), TSCA (United States) and other country-specific registrations. Every consignment ships with up-to-date Safety Data Sheets and full documentation for customs clearance, showing regulatory status and compliance with both local and destination laws. For example, REACH demands preregistration and notification to relevant parties in the supply chain, while the United States DOT classifies Bronopol under UN 3241 for transportation, setting rules for packaging and hazard communication. In Asia-Pacific, certain destinations restrict quantities or demand import permits and extra documentation, a process our logistics coordinators manage directly.
Shipping Bronopol by sea calls for weatherproof containers and desiccants. Our logistics team inspects all export packaging to ensure seals, tamper evidence, and secondary containment for bulk shipments. For air freight, we comply with IATA Dangerous Goods Regulations, including packaging that passes pressure and drop tests, and external hazard markings in line with GHS standards. Internal audits check that warehouses along the supply chain keep moisture below industry thresholds and prevent cross-contamination with incompatible substances such as oxidizers or strong acids. On arrival, our customers receive guidance on interim storage, recommending well-ventilated, dry, covered facilities, away from sources of heat and out of direct sunlight.
Our compliance process draws on audits, staff training, and active dialogue with international partners. It is not enough to meet minimum regulatory requirements. Our team tracks changes in chemical regimes and partners with certified logistics providers who share a record of safe, compliant transport. This approach reduces customs delays and protects the end user while preserving the biocidal efficacy of Bronopol during long-distance shipping. Each batch produced receives a full tracking lot code, allowing rapid response if a regulatory or quality question comes up during transit or at the receiving site.
Decades in chemical manufacturing have taught us that rigorous attention to detail in storage and compliance pays off in product reliability and safety. Most complications in international delivery stem not from manufacturing, but from lapses in storage atmosphere, weak documentation, or gaps in regulatory awareness. By emphasizing sealed containers, clear labelling, robust paperwork, and well-trained personnel from our factory floor to the receiving dock, we maintain a record of reliable, compliant deliveries, even as the regulatory environment becomes more complex. That’s the standard our clients expect and we work daily to maintain.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327